Non-clinical studies have shown that Th2 cytokines, including IL-13, may in fact impair immunity to rhinoviruses or respiratory syncytial virus (RSV) either directly [19,20,21] or indirectly via signal transducer and activator of transcription 6 (STAT6) activation [22] and a recent review [19] summarizes evidence suggesting that blocking IL-33/IL-13 may be beneficial in the treatment of virus-associated lung disease. This evidence concerns the gene IL13 and lung disorder.